The use of fibrinogen concentrate in coagulation testing aids in the diagnosis and management of rare bleeding disorders.

BACKGROUND

Many clinical laboratories lack the methods or resources to quickly identify rare haemorrhagic diseases, such as genetic/acquired fibrinogen defects and factor XIII deficiency.

CASE REPORT: This report explored the value of human fibrinogen concentrate in the diagnosis and management of rare bleeding disorders through three case studies. Case 1 involved acquired hypofibrinogenemia caused by snake bite, where the coagulation abnormality was corrected by adding fibrinogen in vitro, confirming the mechanism of snake venom-specific degradation of fibrinogen. Case 2 utilised fibrinogen solution to establish a thromboelastography mixing test for rapid diagnosis of autoimmune factor XIII inhibitors. Case 3 improved platelet aggregation function in patients with congenital abnormal fibrinogenaemia through fibrinogen solution.

CONCLUSION

These case studies showed that fibrinogen concentrate may serve as a specific additive to assist in the rapid identification of coagulation dysfunction and guide precise treatment.